A

Akebia Therapeutics
D

AKBA

1.79500
USD
-0.11
(-5.53%)
مغلق
حجم التداول
152,706
الربح لكل سهم
-0
العائد الربحي
-
P/E
-8
حجم السوق
391,635,258
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AGEN
    -0.11500
    (-3.34%)
    3.33000 USD
    D
    DVAX
    0.000
    (0.00%)
    13.335 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    K
    KPTI
    -0.00940
    (-1.55%)
    0.59840 USD
    K
    KURA
    0.11500
    (1.41%)
    8.26500 USD
    M
    MGNX
    -0.13000
    (-4.50%)
    2.76000 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    المزيد
الأخبار
المقالات

العنوان: Akebia Therapeutics

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease,in adult patients, HIF-PH inhibitors in preclinical development.